Europe Secondary Progressive Multiple Sclerosis Drug Market was valued at USD 2.5 Billion in 2022 and is projected to reach USD 4.2 Billion by 2030, growing at a CAGR of 7.8% from 2024 to 2030.
The European market for Secondary Progressive Multiple Sclerosis (SPMS) drugs is experiencing significant growth, driven by increasing disease prevalence and advancements in treatment options. SPMS, a stage of multiple sclerosis characterized by progressive neurological decline, necessitates specialized therapeutic interventions.
In 2025, the European SPMS drug market is projected to reach approximately $3.76 billion, with an annual growth rate of 0.93% through 2029. citeturn0search6 This growth is attributed to a combination of factors, including a rising patient population and continuous research and development efforts by pharmaceutical companies.
The market is primarily segmented based on drug class, route of administration, and distribution channel. Key drug classes include immunomodulators, immunosuppressants, and interferons. Oral and injectable forms (intramuscular, subcutaneous, and intravenous) are the main routes of administration. Distribution channels encompass hospital pharmacies, retail pharmacies, and online platforms.
Recent developments highlight the dynamic nature of the SPMS drug market. In September 2023, the European Medicines Agency approved Tyruko (natalizumab-sztn), a biosimilar to Tysabri, offering patients a more affordable treatment option. citeturn0search16 Additionally, Sanofi's tolebrutinib has shown promise in delaying disease progression by 31% in clinical trials, providing renewed hope for effective SPMS management. citeturn0news15
However, the market also faces challenges, including high treatment costs and the need for continuous innovation. Regulatory actions, such as the European Commission's €462.6 million fine against Teva for anti-competitive practices related to its MS drug Copaxone, underscore the importance of maintaining fair competition to ensure patient access to affordable medications. citeturn0news13
In summary, the European SPMS drug market is evolving rapidly, with significant investments in research leading to new treatment options. While challenges remain, ongoing efforts aim to improve patient outcomes and expand access to effective therapies.
Get an In-Depth Research Analysis of the Europe Secondary Progressive Multiple Sclerosis Drug Market Size And Forecast [2025-2032]
Â
AB Science SA
Actelion Ltd
Biogen
Inc
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix
Inc
Immune Response BioPharma
Inc
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co.
Ltd.
Mal Incrodt Plc
MedDay SA
MedImmune
LLC
Merck KGaA
Meta-IQ ApS
Novartis AG
Opexa Therapeutics
Inc
Xenetic Biosciences (UK) Limited
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Secondary Progressive Multiple Sclerosis Drug Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Secondary Progressive Multiple Sclerosis Drug Market
Oral Therapies
Injectable Therapies
Intravenous Therapies
Monoclonal Antibodies
Immunomodulators
Immunosuppressants
Neuroprotectants
Cell-based Therapies
Oral
Subcutaneous
Intravenous
Intramuscular
Disease Modification
Symptom Management
Progression Delay
Quality of Life Improvement
Age Groups
Gender
Socioeconomic Status
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Secondary Progressive Multiple Sclerosis Drug Market Research Analysis
1. Introduction of the Europe Secondary Progressive Multiple Sclerosis Drug Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Secondary Progressive Multiple Sclerosis Drug Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Secondary Progressive Multiple Sclerosis Drug Market, By Type
6. Europe Secondary Progressive Multiple Sclerosis Drug Market, By Application
7. Europe Secondary Progressive Multiple Sclerosis Drug Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. Europe Secondary Progressive Multiple Sclerosis Drug Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/